{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:04:17Z","timestamp":1761581057548,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.clgc.2012.12.002","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T15:18:09Z","timestamp":1359040689000},"page":"100-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"11","author":[{"given":"Lauren C.","family":"Harshman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Barbeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"McMillian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2012.12.002_bib1","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.12.002_bib3","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib4","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2012.12.002_bib5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.12.002_bib6","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2012.12.002_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2012.12.002_bib8","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.12.002_bib10","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib11","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib13","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib14","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2012.12.002_bib15","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial","volume":"30","author":"Motzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.12.002_bib17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00280-010-1507-6","article-title":"A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)","volume":"67","author":"Bullock","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2012.12.002_bib19","doi-asserted-by":"crossref","unstructured":"Zafar Y, Bendel J, Lager J, et al. Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. Proceedings of the American Society of Clinical Oncology Annual Meeting 2006, Atlanta, GA. Abstract #3097.","DOI":"10.1200\/jco.2006.24.18_suppl.3097"},{"key":"10.1016\/j.clgc.2012.12.002_bib20","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib21","unstructured":"Flaherty K, Manola J, Pins M, et al. A randomized phase II study of VEGF, RAF kinase and mTOR combination targeted therapy with bevacizumab, sorafenib and temsirolimus in advanced renal cell carcinoma, in The BeST trial; E204. Presented at the 2012 Kidney Cancer Association Meeting, Chicago, IL, October 5-6, 2012."},{"key":"10.1016\/j.clgc.2012.12.002_bib22","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2007.10.8332","article-title":"Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity","volume":"26","author":"Azad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib23","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/JCO.2008.19.0108","article-title":"Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma","volume":"27","author":"Feldman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"N\u00e9grier","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib25","doi-asserted-by":"crossref","unstructured":"Ravaud A, Anak O, Gogov S, et al. Randomized phase II study of first-line everolimus (EVE) + bevacizumab (BEV) versus interferon alfa-2a (IFN) + BEV in patients (pts) with metastatic renal cell carcinoma (mRCC): record-2. Presented at the 37th Congress of the European Society for Medical Oncology (ESMO). Vienna, Austria, September 28-October 2, 2012.","DOI":"10.1093\/annonc\/mds399"},{"key":"10.1016\/j.clgc.2012.12.002_bib26","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-09-0717","article-title":"A phase I study of sunitinib plus bevacizumab in advanced solid tumors","volume":"15","author":"Rini","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.clgc.2012.12.002_bib27","doi-asserted-by":"crossref","unstructured":"Rini Bi BJ, Alyzasova AV, Clancy J, et al. Randomized phase IIIb trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT. Presented at the 37th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, September 28-October 2, 2012. abstract LBA21.","DOI":"10.1016\/S0923-7534(20)34326-X"},{"key":"10.1016\/j.clgc.2012.12.002_bib28","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2009.26.3152","article-title":"Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma","volume":"28","author":"Hainsworth","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib29","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2009.27.4951","article-title":"How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.12.002_bib30","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-10-2806","article-title":"Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors","volume":"17","author":"Rini","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2012.12.002_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002394","article-title":"Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality","volume":"3","author":"Chan","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clgc.2012.12.002_bib32","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767312002418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767312002418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:22:41Z","timestamp":1761564161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767312002418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1558767312002418"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2012.12.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2012.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}